Press
Release

Human clinical study confirms TendoGuard efficacy for tendon/joint and connective tissue disorders

Certified Nutraceuticals, Inc. is pleased to announce the positive initial results of the ongoing human clinical studies for the efficacy of TendoGuard™ U.S. Patent #8,344,106 B1- Collagen Type I, II, V. X isolated from 100% Avian Eggshell Membrane and Sternum Cartilage. The compositional makeup of TendoGuard produced extraordinary clinical therapeutic value for connective tissue disorders and improved the mobility and activity for individuals with tendon/joint conditions.

Collagen is composed of amino acids responsible for the growth, repair and maintenance of human. The internal composition of Collagen has an abundance of the amino acids glycine and proline. It also contains a good quantity of hydroxyproline and hydroxylysine. These are found in all connective tissue, eyes, skin, nails, hair and bone. Type II collagen is the major component of hyaline cartilage. Collagen Type II has an abundance of hyaluronic acid and mucopolysaccarides.

The Collagen supplements work naturally within the body as a bioavailable food source. Collagen is a protein processed with optimum molecular weight for easy assimilation. Collagen also increases blood circulation because it exhibits one of the elevated metabolic process created. Collagen is a major component in forming ligaments, tendons, muscles and cartilage. As one increase in age, it is difficult to manufacture sufficient amounts of collagen, this is the building block through time leading to arthritis and age related joint pain. Collagen promotes structural recovery from injurious strains of the muscle, tendons, ligaments and cartilage. Collagen is required to mend and restore connective tissue aiding muscle strengthening and better joint mobility.

Arthritic Pain through disease due to inflammatory process reduces mobility within joint area and cavities. Collagen makes mobility possible in joints without any kind of rigidity assisting the treatment and rehabilitation of an individual with arthritic pain to a pre-injurious level with or without structural breakdown. What is known about egg membrane is that it is a novel dietary supplement that contains naturally occurring glycosaminoglycans and proteins essential for maintaining healthy joint and connective tissues. Egg membrane components have been shown to benefit joint and connective tissue flexibility, comfort, and range of motion with minimal known adverse side effects. Egg membrane augments joint and connective tissue health by supplementing body constituents that have been lost through normal life and the aging process.

For this study we chose 15 patients’ ages 17-81 years (eight males / seven females) with confirmed joint damage and cartilage injuries, diagnosed with imaging/scoping with low to high pain scales. The optimal dosage administered is 1,500-2,500mg daily dietary supplement taken with citric juice on an empty stomach.

The above graph identifies the significant pain reduction score response as contributed by the trial participants (expressed as an average). The pain score contributed at the start of the trial by the participants averaged out at the top level being 10. We saw a significant daily reduction in the pain score during the trial period from day 1 (pain score of 10) to 25 days (pain score of 1.5). After 25 days, the participants’ average pain level to symptoms leveled out at a consistently at 1.5 on a scale of 1-10. This indicates a very rapid clinical response of actual symptoms which lends support to the salivary rise of the pH.

Significant findings of 15 positive clinical responses from trial (mixed with clinical comments):

• three participants could not walk any distance over 10m without feeling some discomfort. The same participants were asked to record their walking distance at 75% of trial duration. Respondents recorded from 0.5-2km per day without major discomfort as felt prior to the trial.
• one participant improved greatly enough to cancel his diagnostic arthroscopy in the interim while taking
  TendoGuard.
• one participant reported not only an overall improvement in joint pain and mobility, but also a persistent acute oral eruption problem present for over 2 years dissipated while mid-way into the trial.
• four participants who were seniors presented an overall average of 77% improvement scale in "stiffness" and
  "tenderness" during normal exertion.
• 15 participants with total joint pain (vertebral/knee/shoulder/pelvic) indicated increased mobility average at 79%
  improving their pain scale average of > 5 to < 3 – standard pain scale of 1-10
• four patients with knee and hip pain associated with confirmed Fibromyalgia and CFS noted an overall increase in their pain index by 70%
• one participant’s finger nail quality improved from rippled (a sign of severe inflammatory process within the body) to non-rippled/normal appearance
• 40% of Participants also noted that minor chronic skin blemishes on the face and hairline improved greatly while participating in the trial.
• two participants noted that they had a weight loss factor of >2 Kg’s, likely due to either a natural process or
  metabolic increase of the physiological state.
• No discernible differences between male or female and/or age group in order to acquire a positive clinical response.

Targeted clinical response results

Supplementation with TendoGuard produced a significant treatment response at seven days for flexibility (29.6% increase; P = 0.036) and at 30 days for general pain (84.1% reduction; P = 0.006), flexibility (45.5% increase; P = 0.005), and range of motion associated pain (74.7% reduction; P = 0.020). The substantial treatment response continued through 30 days for pain (68.3% reduction; P = 0.0001). There were no adverse events reported during the study and the treatment was reported to be well tolerated by study participants. Salivary pH tracking showing normalization of pH in participants indicates the average pH taken at the commencement of the trial (day 1) and followed to the end response time of the trial (30 days). During an inflammatory state within the body, the pH of saliva drops considerably as a secondary response to the inflammation. As per the graph, we see an incremental rise at day one plus followed to day 30 when we see that the salivary pH is normalizing to that of a healthy individual (asymptomatic for all conditions/disease process). Studies and testing indicate that the normal/optimal pH for saliva is of 7.34 to 7.45 respectively. By the time the individuals had taken TendoGuard™ for 30 days, the participants’ pH normalized to a symptom free individual.

Conclusion

TendoGuard is a novel dietary preparation when taken at a dosage of 375-500mg twice per day which benefits joint inflammation, secondary mobility and other tertiary effects. TendoGuard naturally contains anti-inflammatory compounds and aids in the support for joint and/or tendon abnormalities. TendoGuard systemically works to retain and preserve healthy structure anatomical placements namely tendon, bone, joint, cartilaginous structures. This study demonstrates that TendoGuard may be a viable treatment option for the management of joint and connective tissue disorders. TendoGuard 375- 500mg taken once or twice daily significantly reduced pain by a rapid response at seven days and continuously at 30 days. Noted with further study TendoGuard benefits other varied clinical and nuisance disorders

The ongoing Human Clinical Trial is performed by Morton Scientific Group of Cambridge, Ontario, Canada and overseen by qualified Medical Doctors. Certified Nutraceuticals supplies the world market with TendoGuard ™ in bulk powder which is manufactured at FDA – USDA approved facility and proudly promotes the products as Made in USA.

Our advantage is the exclusive proprietary water extraction technology process to extract denatured Avian Eggshell Membrane and Sternum Cartilage to produced Collagen Type I, II, V, X Powder without the use of solvent (ethanol) or harsh chemicals. This process preserves important nutrients and molecules to yield more Hyaluronic Acid (HA) and more Chondroitin for optimum assimilation to help damaged cartilage.

Certified Nutraceuticals’ visionary CEO and the original inventor, Mr. Ahmad Alkayali, first introduced Hydrolyzed Chicken Collagen Type II in 1995. Since then continued research and improvement by our innovation team is the result of this new advanced invention. Mr. Alkayali was the first to introduce collagen supplements to the market more than a quarter of a century ago. Certified Nutraceuticals specializes in innovative quality collagen and anti-aging nutrients for longevity and good health. We developed Patented Pomegranate Ellagic70™ extracted from the seed with powerful Ellagic acid and Punicalagins; Revers♥e-vine® (patent pending) grapevine extract antioxidant featuring the newly discovered Trans-e-Viniferin, which is considered to have more antioxidant effects beyond resveratrol; H.A.95™ Natural Hyaluronic acid synovial fluid to lubricate healthy joints; Olea25® (patent pending) 25% Hydroxytyrosol powder extracted from organic olive leaf with the highest ORAC value of any botanical ingredient discovered to date, patented kollaGen II-xs™; and our newest discovery of the Century- Telos95® – Telomere Health Support ingredient.

TendoGuard – Collagen Type I, II, V, X and mucopolysaccharides for keeping tendons healthy and flexible, can be made easily into capsules, tablets, beverages, functional foods and cosmetic applications.

For more information please visit our web-site at www.certifiednutra.com, or contact us at (951) 600-3899.